On March 15, 2023 AimedBio and Genequantum healthcare reported the preclinical study result of co-developing FGFR3-ADC ‘AMB302/GQ1011’ will be presented at the "World ADC".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– They have confirmed AMB302/GQ1011’s anti-tumor effect in both bladder cancer and GBM cancer models, and plan to submit IND and start phase 1 clinical trial in 1H 2024.

(Press release, AimedBio, MAR 15, 2023, View Source;s_keyword=&s_where=&start=20 [SID1234656921])